Send Message
Home News

company news about Viral Hepatitis: A Global Health Challenge

China Hangzhou AllTest Biotech CO.,LTD certification
Customer Reviews
We recently started selling your HCG tests via our Australian partner and have been very impressed with the quality and consistency of the tests. They seem to be superior to our current manufacturer and we also know that you are far more reliable in terms of production times and communication.

—— One customer from Europe

We would like to explore the possibility of switching our HCG tests over to you. We have been reluctant in the past to move everything over to you as it makes us very reliant on you. However, we have always found you to be by far the most reliable of all our Chinese manufacturers and so we feel comfortable strengthening our partnership further

—— One customer from Europe

I like the products and service provided by AllTest. They really take our interest into consideration.

—— Mr John Smith England

My oldest daughter actually has Lyme disease. She spent almost 1 year in a wheelchair because of Lyme. She is doing very well now. I used 2 of the samples. 1 to test my Lyme diagnosed daughter and 1 to test my daughter who does not have Lyme. Your tests worked well. My daughter with Lyme tested positive and the one who does not tested negative.

—— Ms Sheila

Whenever I have the requests,AllTest always give me the satisfied reply at the first time.

—— Mrs Julie Tschetter Belgium

As the old customer of AllTest since 2009, we should thank the great work have been done by AllTest to support us gain more market share and profit

—— Mr Robin Seifert Germany

I'm Online Chat Now
Company News
Viral Hepatitis: A Global Health Challenge
Latest company news about Viral Hepatitis: A Global Health Challenge

Recent reports from the World Health Organization (WHO) reveal a concerning global trend of increasing hepatitis infections and deaths. Hepatitis has become the second most common infectious cause of death globally among non-COVID communicable diseases, with viral hepatitis deaths rising to 1.3 million in 2022, up from 1.1 million in 2019. Of these, 83% were caused by hepatitis B and 17% by hepatitis C. Every day, there are 3500 people dying globally due to hepatitis B and C infections.


The burden of viral hepatitis is substantial, affecting a significant number of individuals globally. In 2022, an estimated 254 million people were living with hepatitis B, while 50 million were living with hepatitis C. Half of the burden falls on individuals aged 30-54 and men account for 58% of all cases.


The burden of viral hepatitis exhibits regional variations. The WHO African Region bears the highest burden of new hepatitis B infections, whereas the Western Pacific Region has the highest percentage of hepatitis B-related deaths. Bangladesh, China, Ethiopia, India, Indonesia, Nigeria, Pakistan, the Philippines, Russia and Vietnam shoulder nearly two-thirds of the global burden of hepatitis B and C.


Diagnosis and treatment coverage for viral hepatitis fall significantly below global targets. Only 13 percent of patients with chronic hepatitis B are diagnosed and only 3 percent receive antiviral treatment. Hepatitis C is diagnosed in 36% of cases and only 20% of patients receive treatment.


To address these challenges, immediate action is required. Efforts should focus on increasing awareness and prevention, expanding affordable testing and diagnostic services, improving treatment coverage, strengthening healthcare systems, addressing regional disparities and advocating for policy change. Collaboration between Governments, healthcare organizations and civil society are essential to effectively combat viral hepatitis and reduce its devastating impact globally.

Pub Time : 2024-04-22 08:48:44 >> News list
Contact Details
Hangzhou AllTest Biotech CO.,LTD

Contact Person: Mrs. Selina

Tel: 86-13989889852

Send your inquiry directly to us (0 / 3000)